# Experimental Drug DT-109 Reverses Fatty Liver Disease via Gut Microbiota Targeting the gut-liver axis offers a novel therapeutic approach for managing MASH progression. - **Source:** [Latest Science News -- ScienceDaily](https://brifing.si/source/0eef8637-6c5b-4e79-8f5b-6c9c6b36cf16) - **Published:** 2026-10-17 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/7875e19b-7dc2-4027-aa00-41855f4e8513 ## Targeting the Gut-Liver Axis Researchers at Michigan Medicine identified a novel strategy for treating metabolic dysfunction-associated steatohepatitis, known as MASH. By utilizing an experimental compound called DT-109, the team successfully reversed severe liver damage in animal models. This approach shifts the therapeutic focus from the liver itself to the gut, addressing the root cause of inflammation. ## Mechanism of Liver Damage The study highlights how excessive growth of Clostridium perfringens bacteria produces ammonia, which compromises the intestinal barrier. This breach allows harmful microbial products to enter the bloodstream and reach the liver. Once there, these toxins trigger inflammatory responses and activate CD8+ T cells, which significantly accelerate the progression of liver disease. ## Compound Efficacy and Function DT-109 is a glycine-based tripeptide designed to modulate gut microbiota and reinforce the intestinal lining. By reducing harmful bacterial populations and ammonia production, the drug prevents systemic translocation of toxins. Experiments in mice and nonhuman primates confirmed that this intervention effectively lowers liver inflammation and mitigates the severity of MASH conditions. ## Broader Cardiovascular Potential Beyond liver health, DT-109 shows promise in addressing systemic metabolic disorders. Previous research indicates the compound can reduce atherosclerotic plaques and prevent vascular calcification in nonhuman primates. Because metabolic diseases often affect multiple organ systems simultaneously, this dual-action potential makes the drug a significant candidate for treating complex, multi-organ inflammatory conditions. ## Clinical Relevance and Future MASH affects approximately 7% of the global population, often progressing to cirrhosis or liver failure. While current treatments remain limited, the ability of DT-109 to repair the gut barrier offers a new therapeutic avenue. Researchers are now focused on advancing the compound toward human clinical trials to establish safety and efficacy profiles. ## Commercial and Research Context The University of Michigan holds the patent for DT-109 and has licensed the technology to Diapin Therapeutics. Senior author Eugene Chen and the university maintain ownership interests in the company, which provided the compound for these studies. This collaboration facilitates the ongoing development and testing required to transition from animal models to human applications. ## Rigorous Ethical Oversight The research adhered to strict institutional and international standards for animal care and clinical study protocols. Approvals were secured from multiple review boards, including the First Affiliated Hospital of Xi'an Jiaotong University and the University of Hong Kong. These measures ensure that all experimental procedures align with established guidelines for scientific integrity and safety. ## Shifting Therapeutic Paradigms This discovery underscores a fundamental shift in treating fatty liver disease by targeting the digestive system. By restoring gut integrity, scientists may prevent liver damage before it becomes irreversible. If confirmed in human trials, this approach could provide a transformative option for patients suffering from chronic metabolic dysfunction and associated cardiovascular complications. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/10/261016080912.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._